Search Results - "Meadows–Shropshire, S." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Belatacept‐Based Immunosuppression in De Novo Liver Transplant Recipients: 1‐Year Experience From a Phase II Randomized Study

Belatacept‐Based Immunosuppression in De Novo Liver Transplant Recipients: 1‐Year Experience From a Phase II Randomized Study

by Klintmalm, G. B., Feng, S., Lake, J. R., Vargas, H. E., Wekerle, T., Agnes, S., Brown, K. A., Nashan, B., Rostaing, L., Meadows‐Shropshire, S., Agarwal, M., Harler, M. B., García‐Valdecasas, J.‐C.
Published in American journal of transplantation (01.08.2014)

Get full text

Journal Article

Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

by KLINTMALM, G. B, FENG, S, AGARWAL, M, HARLER, M. B, GARCIA-VALDECASAS, J.-C, LAKE, J. R, VARGAS, H. E, WEKERLE, T, AGNES, S, BROWN, K. A, NASHAN, B, ROSTAING, L, MEADOWS-SHROPSHIRE, S
Published in American journal of transplantation (01.08.2014)

Get full text

Journal Article

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032

by Rosenberg, J.E., Sharma, P., de Braud, F.G.M., Basso, U., Calvo, E., Bono, P., Morse, M., Ascierto, P.A., Lopez-Martin, J.A., Brossart, P., Rohrberg, K.S., Reguart, N., Lin, W.H., Meadows-Shropshire, S., Saci, A., Callahan, M., Siefker-Radtke, A.O.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

SAT0189 Comparative analysis of alternative outcome measures for use in lupus nephritis trials

SAT0189 Comparative analysis of alternative outcome measures for use in lupus nephritis trials

by Wofsy, D., Meadows–Shropshire, S., Hillson, J., Diamond, B.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

SAT0185 Efficacy and safety of abatacept in lupus nephritis

SAT0185 Efficacy and safety of abatacept in lupus nephritis

by Furie, R., Nicholls, K., Cheng, T.T., Houssiau, F., Burgos-Vargas, R., Chen, S.L., Hillson, J., Meadows-Shropshire, S., Kinaszczuk, M., Merrill, J.T.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816

PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816

by Forde, P.M., Peters, S., Donington, J., Meadows-Shropshire, S., Tran, P., Lucherini, S., Coronado Erdmann, C., Sun, H., Cascone, T.
Published in Journal of thoracic oncology (01.10.2024)

Get full text

Journal Article

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

by Furie, Richard, Nicholls, Kathy, Cheng, Tien‐Tsai, Houssiau, Frederic, Burgos‐Vargas, Ruben, Chen, Shun‐Le, Hillson, Jan L., Meadows‐Shropshire, Stephanie, Kinaszczuk, Michael, Merrill, Joan T.
Published in Arthritis & rheumatology (Hoboken, N.J.) (01.02.2014)

Get full text

Journal Article

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

by Provencio Pulla, M., Forde, P.M., Spicer, J.D., Wang, C., Lu, S., Mitsudomi, T., Awad, M.M., Felip, E., Broderick, S., Swanson, S.J., Brahmer, J.R., Kerr, K.M., Saylors, G., Tanaka, F., Chen, K-N., Tran, M.P., Cai, J.L., Mahmood, J., Meadows-Shropshire, S., Girard, N.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

by Cascone, T., Awad, M.M., Spicer, J.D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J.M., Cornelissen, R., Havel, L., Kuzdzal, J., Petruzelka, L.B., Wu, L., Pujol, J-L., Ito, H., Coronado Erdmann, C., Sathyanarayana, P., Meadows-Shropshire, S., Provencio Pulla, M.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

by Reck, M., Ciuleanu, T.-E., Dols, M.C., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Vidal, O.J., Alexandru, A., Sakai, H., Scherpereel, A., Lu, S., John, T., Carbone, D.P., Meadows-Shropshire, S., Yan, J., Paz-Ares, L.G.
Published in Journal of thoracic oncology (01.01.2021)

Get full text

Journal Article

98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

by Paz-Ares, L., Ciuleanu, T-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Scherpereel, A., Reck, M., Lu, S., John, T., Meadows-Shropshire, S., Balli, D., Agrawal, S., Carbone, D.P.
Published in Journal of thoracic oncology (01.04.2021)

Get full text

Journal Article

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

by Rosenberg, J.E., Sharma, P., de Braud, F.G.M., Basso, U., Calvo, E., Bono, P., Morse, M., Ascierto, P.A., Lopez-Martin, J.A., Brossart, P., Rohrberg, K.S., Reguart, N., Lin, W.H., Meadows-Shropshire, S., Saci, A., Callahan, M., Siefker-Radtke, A.O.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

LBA32Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

LBA32Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

by Rosenberg, J E, Sharma, P, de Braud, F G M, Basso, U, Calvo, E, Bono, P, Morse, M, Ascierto, P A, Lopez-Martin, J A, Brossart, P, Rohrberg, K S, Reguart, N, Lin, W H, Meadows-Shropshire, S, Saci, A, Callahan, M, Siefker-Radtke, A O
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study

LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study

by Awad, M., Cascone, T., Spicer, J., He, J., Lu, S., Tanaka, F., Cornelissen, R., Karaseva, N., Kuzdzal, J., Petruzelka, L.B., Wu, L., Pujol, J-L., Ito, H., Ciuleanu, T-E., Koch, L.D.O.M., Janssens, A., Erdmann, C. Coronado, Sathyanarayana, P., Meadows-Shropshire, S., Pulla, M. Provencio
Published in ESMO open (01.03.2024)

Get full text

Journal Article

121P Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC

121P Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC

by Spicer, J., Pulla, M. Provencio, Awad, M., He, J., Lu, S., Tanaka, F., Cornelissen, R., Petruzelka, L.B., Kuzdzal, J., Wu, L., Pujol, J-L., Ito, H., Ciuleanu, T-E., Koch, L.D.O.M., Janssens, A., Blum, S.I., Vo, L., Erdmann, C. Coronado, Meadows-Shropshire, S., Cascone, T.
Published in ESMO open (01.03.2024)

Get full text

Journal Article

Analysis of Mixtures of Drugs/Chemicals along a Fixed-Ratio Ray without Single-Chemical Data to Support an Additivity Model

Analysis of Mixtures of Drugs/Chemicals along a Fixed-Ratio Ray without Single-Chemical Data to Support an Additivity Model

by Meadows-Shropshire, Stephanie L., Gennings, Chris, Carter, W. Hans, Simmons, Jane Ellen
Published in Journal of agricultural, biological, and environmental statistics (01.12.2004)

Get full text

Journal Article

Sample size and power determination for detecting interactions in mixtures of chemicals

Sample size and power determination for detecting interactions in mixtures of chemicals

by Meadows-Shropshire, S.L, Gennings, C, Carter, W.H. Jr
Published in Journal of agricultural, biological, and environmental statistics (01.03.2005)

Get full text

Journal Article